Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,451 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6
Industry P/E
--
EV/EBITDA
-22.3
Div. Yield
0 %
Debt to Equity
--
Book Value
$17.1
EPS
$-5.8
Face value
--
Shares outstanding
73,181,747
CFO
$-229.30 Mln
EBITDA
$-299.58 Mln
Net Profit
$-272.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nuvalent Inc (NUVL)
| -3.9 | -7.0 | -7.1 | 30.7 | 51.8 | -- | -- |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Nuvalent Inc (NUVL)
| 28.5 | 6.3 | 147.1 | 56.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nuvalent Inc (NUVL)
|
96.7 | 7,450.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 |
| 57.8 | 7,888.0 | 1,091.0 | 202.3 | 31.6 | 31.3 | 35.2 | 13.9 | |
| 62.5 | 7,599.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 41.5 | 11,065.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.8 | 5.0 | |
| 84.6 | 11,173.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 61.6 | 7,485.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.7 | 153.4 | |
| 7.4 | 8,708.1 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 510.7 | 10,120.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 451.2 | 12,842.8 | 2,530.2 | 451.1 | 21.3 | 70.2 | 29.6 | 28.5 | |
| 290.1 | 8,308.2 | 0.0 | -303.3 | -- | -45.8 | -- | 9.5 |
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges... of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Read more
CEO, President & Director
Dr. James R. Porter Ph.D.
CEO, President & Director
Dr. James R. Porter Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nuvalent Inc (NUVL) is $96.66 (NASDAQ) as of 27-Mar-2026 16:00 EDT. Nuvalent Inc (NUVL) has given a return of 51.82% in the last 3 years.
Since, TTM earnings of Nuvalent Inc (NUVL) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-17.26
|
5.88
|
|
2024
|
-19.81
|
4.83
|
|
2023
|
-33.82
|
6.09
|
|
2022
|
-20.30
|
3.22
|
|
2021
|
-9.04
|
1.47
|
The 52-week high and low of Nuvalent Inc (NUVL) are Rs 113.02 and Rs 55.54 as of 28-Mar-2026.
Nuvalent Inc (NUVL) has a market capitalisation of $ 7,451 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nuvalent Inc (NUVL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.40
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.